Sanders Morris Harris LLC Makes New $472,000 Investment in GSK plc (NYSE:GSK)

Sanders Morris Harris LLC acquired a new position in shares of GSK plc (NYSE:GSK) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 13,360 shares of the pharmaceutical company’s stock, valued at approximately $472,000.

Other large investors also recently bought and sold shares of the company. Centerpoint Advisors LLC increased its stake in GSK by 115.8% during the 1st quarter. Centerpoint Advisors LLC now owns 846 shares of the pharmaceutical company’s stock worth $30,000 after buying an additional 454 shares in the last quarter. GW&K Investment Management LLC increased its stake in GSK by 215.3% during the 1st quarter. GW&K Investment Management LLC now owns 1,110 shares of the pharmaceutical company’s stock worth $39,000 after buying an additional 758 shares in the last quarter. SRS Capital Advisors Inc. increased its stake in GSK by 52.9% during the 1st quarter. SRS Capital Advisors Inc. now owns 1,090 shares of the pharmaceutical company’s stock worth $39,000 after buying an additional 377 shares in the last quarter. WealthPlan Investment Management LLC purchased a new stake in shares of GSK in the first quarter valued at approximately $42,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC grew its position in shares of GSK by 61.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock valued at $42,000 after purchasing an additional 368 shares in the last quarter. 13.53% of the stock is currently owned by hedge funds and other institutional investors.

GSK Trading Up 0.1 %

GSK opened at $37.43 on Friday. GSK plc has a one year low of $28.47 and a one year high of $39.74. The stock has a market capitalization of $76.64 billion, a PE ratio of 4.27, a P/E/G ratio of 1.95 and a beta of 0.68. The business’s 50 day moving average price is $35.21 and its 200 day moving average price is $35.36. The company has a debt-to-equity ratio of 1.28, a quick ratio of 0.63 and a current ratio of 0.88.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. GSK had a return on equity of 55.93% and a net margin of 50.26%. The firm had revenue of $8.98 billion for the quarter, compared to analysts’ expectations of $8.49 billion. As a group, equities research analysts expect that GSK plc will post 3.77 EPS for the current year.

GSK Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 18th will be paid a dividend of $0.3613 per share. This represents a $1.45 dividend on an annualized basis and a yield of 3.86%. The ex-dividend date of this dividend is Thursday, August 17th. GSK’s dividend payout ratio (DPR) is 16.10%.

Analyst Upgrades and Downgrades

GSK has been the subject of a number of analyst reports. HSBC initiated coverage on GSK in a research report on Friday, July 14th. They issued a “reduce” rating for the company. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 2nd. Four equities research analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $1,533.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.